<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SLC2A5 Gene</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>SLC2A5</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>SLC2A5</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=SLC2A5" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
The SLC2A5 gene encodes the GLUT5 protein (Glucose Transporter 5), which is a member of the solute carrier family 2 (SLC2) of facilitative glucose transporters. GLUT5 is primarily responsible for fructose transport across cellular membranes and is expressed in various tissues including the small intestine, kidney, testis, and brain. This gene plays a crucial role in carbohydrate metabolism and has emerged as a subject of interest in neurodegenerative disease research due to the metabolic alterations observed in conditions like Alzheimer's disease and Parkinson's disease.
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SLC2A5 Gene</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>SLC2A5</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>SLC2A5</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=SLC2A5" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
The SLC2A5 gene encodes the GLUT5 protein (Glucose Transporter 5), which is a member of the solute carrier family 2 (SLC2) of facilitative glucose transporters. GLUT5 is primarily responsible for fructose transport across cellular membranes and is expressed in various tissues including the small intestine, kidney, testis, and brain. This gene plays a crucial role in carbohydrate metabolism and has emerged as a subject of interest in neurodegenerative disease research due to the metabolic alterations observed in conditions like Alzheimer's disease and Parkinson's disease.
SLC2A5 was originally identified as a fructose-specific transporter with highest expression in the small intestine where it facilitates dietary fructose absorption [@slc2a5_overview]. However, subsequent research has revealed that GLUT5 is also expressed in the brain, particularly in specific regions involved in sensory processing and cognitive functions [@glut5_brain]. The discovery of fructose transport capability in neuronal cells has opened new avenues of research exploring the relationship between fructose metabolism and neurodegeneration.
The significance of SLC2A5 in neurodegenerative diseases stems from the growing evidence that metabolic dysfunction, including altered glucose and fructose metabolism, plays a pivotal role in the pathogenesis of Alzheimer's disease and Parkinson's disease [@neuroenergetics]. The brain's reliance on continuous glucose supply for normal function, combined with the observation that insulin signaling in the brain is disrupted in neurodegenerative conditions, has led researchers to investigate how various sugar transporters, including GLUT5, may contribute to disease progression.
SLC2A5 encodes the facilitative fructose transporter GLUT5, a 501-amino acid protein that facilitates the bidirectional transport of fructose across cell membranes [@fructose_transport]. Unlike sodium-dependent glucose transporters, GLUT5 operates via facilitative diffusion, allowing fructose to move across the plasma membrane down its concentration gradient. The transporter exhibits substrate specificity for fructose, with minimal activity toward glucose or other hexoses.
The protein structure of GLUT5 has been characterized through cryo-electron microscopy studies, revealing the structural basis for fructose recognition and transport [@glut5_structure]. The transporter adopts a typical major facilitator superfamily conformation with 12 transmembrane helices forming a translocation pathway that alternates between outward-facing and inward-facing conformations during the transport cycle.
GLUT5 expression is highest in the small intestine, where it plays a critical role in dietary fructose absorption [@fructose_transport]. In the kidney, GLUT5 is expressed in the proximal tubules where it contributes to fructose reabsorption. Testicular expression has also been documented, suggesting a role in male fertility. Within the brain, GLUT5 expression has been detected in specific regions including the primary somatosensory cortex [@glut5_expression], hippocampus, and hypothalamus.
GLUT5 expression is regulated at multiple levels, including transcriptional control and post-translational modifications. Dietary fructose intake has been shown to upregulate GLUT5 expression in the intestine through mechanisms involving carbohydrate response element-binding proteins (ChREBP) and peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α) [@gut_brain_axis]. High glucose conditions can also modulate GLUT5 expression through insulin-dependent signaling pathways [@glut5_insulin].
The potential link between SLC2A5/GLUT5 and Alzheimer's disease (AD) has gained attention due to the growing evidence connecting fructose metabolism with neurodegenerative processes [@fructose_alzheimers]. Several mechanisms have been proposed:
The broader relationship between metabolic syndrome and neurodegenerative diseases has been extensively documented [@metabolic_synd_neurdegeneration]. Type 2 diabetes mellitus (T2DM) is a significant risk factor for AD, with shared mechanisms including insulin resistance, chronic inflammation, and mitochondrial dysfunction [@t2dm_alzheimers]. SLC2A5 dysfunction may contribute to this metabolic phenotype through its effects on fructose handling and insulin sensitivity.
While research on SLC2A5 in Parkinson's disease (PD) is more limited, the established connections between metabolic dysfunction and PD pathogenesis suggest potential involvement. Altered glucose metabolism has been documented in PD brains, and mitochondrial dysfunction is a central feature of dopaminergic neuron degeneration in PD. Further research is needed to establish specific mechanisms linking GLUT5 to PD.
GLUT5 expression in the brain is region-specific and differs from other glucose transporters. Unlike GLUT1 (encoded by SLC2A1) which is widely expressed in the blood-brain barrier and glia, or GLUT3 (encoded by SLC2A3) which is the primary neuronal glucose transporter, GLUT5 shows more restricted distribution.
Immunocytochemical studies have demonstrated GLUT5 expression in the rat primary somatosensory cortex [@glut5_expression]. This finding suggests a potential role for GLUT5 in processing somatosensory information, although the exact functional significance remains to be fully elucidated.
The hippocampus, a brain region critical for learning and memory and severely affected in AD, shows GLUT5 expression. This localization suggests that fructose transport may play a rolesynaptic function and neuronal energy metabolism in memory-related circuits.
The hypothalamus, which regulates metabolic homeostasis and contains glucose-sensing neurons, expresses GLUT5. This expression may be relevant to the hypothalamic dysfunction observed in metabolic disorders and neurodegenerative diseases.
Understanding SLC2A5 function and regulation has several therapeutic implications: